H.P. Acthar® Gel (repository corticotropin injection) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.

Updated November 2018

Nephrology


Neurology


89. Due BR, Becker PM, Coyle PK. A prospective observational registry of repository corticotropin injection for the treatment of multiple sclerosis relapse: baseline characteristics and interim results [CMSC abstract RT02] *Int J MS Care*. 2018;20(suppl 1):89.

113. English JB, Strickland S, English PJ. Methylprednisolone treatment, patient reported

infantile spasms. Epilepsy Behav. 2016;59:4-8. Link

111. Hrachovy RA, Frost JD, Glaze DG. High-dose, long-duration versus low-dose, short-duration

110. Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone

109. Hrachovy RA, Frost JD, Kellaway P, Zion T. A controlled study of ACTH therapy in infantile

Link

assess current practice patterns of MS relapse assessment and treatment among MS

106. Knupp KG, Leister E, Coryell J, Nickels KC, Ryan N, Juarez-Colunga E, Gaillard WD,
Mytinger JR, Berg AT, Millichap J, Nordli DR Jr, Joshi S, Shellhaas RA, Loddenkemper T,
Dlugos D, Wirrell E, Sullivan J, Hartman AL, Kossos EH, Grinspan ZM, Hamikawa L.
Response to second treatment after initial failed treatment in a multicenter prospective

multicenter initiative to improve treatment and outcomes of infantile spasms: Etiologies, initial


103. Kossos EH, Hedderick EF, Turner Z, Freeman JM. A case-control evaluation of the ketogenic

Cognitive changes in Multiple Sclerosis patients treated with subcutaneous
adrenocorticotropic hormone for acute relapse. [ECTRIMS abstract P1111]. ECTRIMS Online
Library.2016;145795.

101. Kutz C. H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple

100. Kutz CF. Repository corticotropin injection relapse treatment in patients with multiple


98. Lehrer GM. Treatment of MS with Acthar Gel-clinical experience and case presentation [ANA

Epilepsia. 1983;24(2):135-158. Link

96. Molitor RE, Stewart J. Home intravenous administration of adrenocorticotropic hormone in

95. Mytinger JR, Weber A, Heyer GL. The response to ACTH is determined early in the treatment
of infantile spasms [AES abstract 3.144]. Epilepsy Curr. 2014;14(suppl 1):360

94. Mytinger JR, Weber A, Heyer GL. The response to ACTH is determined early in the treatment
of infantile spasms. Epilepsia. 2015;17(1):52-57. Link

93. Murray S., Woo A. Clinical experience with repository corticotropin injection in patients with
multiple sclerosis experiencing mood changes with intravenous methylprednisolone: A case


91. Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA. Impact of multiple
sclerosis relapse: The NARCOMS participant perspective. Mult Scler Relat Disord.
2015;4(3):234-240. Link


**Neurology – HEOR**


154. Hansen R, Gold L, Schepman P, Niewoehner J, Philbin M. Economic consequences of early versus late use of adrenocorticotropic hormone therapy in infantile spasms [WCI abstract LB10]. Late-breaker abstract presented at World Congress of Inflammation Meeting; August 8-12, 2015; Boston, MA. 2015


Ophthalmology


Ophthalmology HEOR


Pulmonology


**Pulmonology – HEOR**


**Rheumatology**


Fernandez A. Interim results of an open-label study assessing efficacy and safety of adrenocorticotropic hormone gel for treatment of refractory cutaneous manifestations of dermatomyositis [ACR abstract 2287]. *Arthritis Rheumatol.* 2018;70(S9):2520-2521.


Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. *Lupus.* 2014;23(9):905-912. Link


222. Gaylis N, Needell S, Sagliani J. The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI [EULAR abstract AB0503]. *Ann Rheum Dis.* 2015;74(suppl 2):1066-1067


224. Gillis TM, Crane M, Hinkle C, Wei N. H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action [EULAR abstract AB0502]. *Ann Rheum Dis.* 2015;74(suppl 2):1066-1066


244. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. Arch Dis Child. 1971;46(249):584-593. Link

Rheumatology – HEOR


Other


Clemson CM, Yost J, Taylor AW. The role of alpha-MSH as a modulator of ocular immunobiology exemplifies mechanistic differences between melanoctins and steroids. *Ocul Immunol Inflamm.* 2016;1-11. [Link](#)


Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. *J Immunol.* 2015;194(suppl 1):139.4-139.4


308. Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel [ASN abstract SA-PO381]. J Am Soc Nephrol. 2012;23(suppl):725A


310. Jensen MA, Abraham P, Reder AT, Arnason BGW. Co-production of GM-CSF, IL-22, or IL-17F identifies a pathogenic high IL-17A-producing T cell subset from MS patients that is steroid resistant [ANA abstract S151]. Ann Neurology. 2016;80:S53-S54. 


314. Kongelbeck SR. Discharge planning for the child with infantile spasms. J Neurosci Nurs. 1990;No. 4:238-244. Link


325. Lisak RP, Nedelkoska L, Benjamins JA. Melanocortin 4 receptors on oligodendrocytes and oligodendrocyte precursors signal ACTH protection from in vitro death induced by mechanisms involved in cell damage in multiple sclerosis. [ECTRIMS abstract P579]. *Mult Scler.* 2015;23(11 suppl 1):273,

326. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. *Neurology.* 2015;84(suppl 14):P2.189


338. Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin
injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. Ann Rheum Dis. 2013;72(suppl 3):904


